Cancer Insurance Sales Increase
Aflac Japan reported a 12.6% year-over-year sales increase, with a significant contribution from a 6.3% increase in cancer insurance sales.
Adjusted Earnings Per Share Stable
Adjusted earnings per diluted share were $1.66, unchanged from the first quarter of 2024, despite a $0.01 negative impact from foreign exchange.
Strong Capital Deployment
Aflac deployed $900 million to repurchase 8.5 million shares of stock and delivered $1.2 billion back to shareholders, maintaining a strong capital position.
U.S. Sales Growth
Aflac U.S. saw a 3.5% year-over-year increase in sales, with strong momentum in group life, disability, and dental segments.
High Persistency Rates
Persistency rates remained high in both Japan (93.8%) and the U.S. (79.3%), indicating customer retention and business stability.